It’s not an easy environment for health-care investors, with the sector front and center of political debates, but a bigger concern might be stemming from a key regulator: the U.S. Food and Drug Administration.

BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at approximately $67.0 million.

How cool is this: the Massachusetts General Hospital (MGH) laboratory that invented cryolipolisis or “Coolsculpting,” a popular non-surgical method for reducing fat under the skin, is developing a new form of the technology that can selectively reduce fat almost anywhere in the body using a safe, injectable ice solution or “slurry.”

A new study shows how tiny robotic vessels powered by acoustic waves and an on-board bubble motor can be maneuvered through cellular landscapes using magnets.